The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Official Title: A Multi-Center, Phase II, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Photobiomodulation for the Treatment of Oral Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (the LIGHT Trial)
Study ID: NCT05675930
Brief Summary: The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
Detailed Description:
Minimum Age: 4 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
National Institute of Health (Data Collection AND Specimen Analysis), Bethesda, Maryland, United States
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Bergen (Consent only), Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Commack (Consent only), Commack, New York, United States
Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Memorial Sloan Kettering Cancer Center @ Nassau (Consent only), Uniondale, New York, United States
University of Pittsburgh Medical Center (Data Collection Only), Pittsburgh, Pennsylvania, United States
Name: Alina Markova, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR